Teneliximab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 470601929

| image =

| type = mab

| mab_type = mab

| source = xi/o

| target = CD40

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 299423-37-3

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = G0MV33WQ6V

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D06071

| chemical_formula =

| molecular_weight =

}}

Teneliximab is a chimeric monoclonal antibody[https://web.archive.org/web/20091016232326/http://whqlibdoc.who.int/druginfo/INN_2003_list49.pdf International Nonproprietary Names For Pharmaceutical Substances] binding to the immune stimulatory protein CD40.{{cite book | vauthors = Law CL, Grewal IS | title = Therapeutic Targets of the TNF Superfamily | chapter = Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges | series = Advances in Experimental Medicine and Biology | volume = 647 | pages = 8–36 | date = 2009 | pmid = 19760064 | doi = 10.1007/978-0-387-89520-8_2 |publisher=Springer Science+Business Media |location=New York, N.Y. |isbn=978-0-387-89520-8 | chapter-url = https://books.google.com/books?id=GMr1VYauOt0C&dq=Teneliximab&pg=PA24 }} {{as of|2009}}, it has not entered clinical trials.